Tadekinig alfa - AB2 Bio

Drug Profile

Tadekinig alfa - AB2 Bio

Alternative Names: IL-18BP - AB2 Bio; Recombinant human IL-18 binding protein - AB2 Bio

Latest Information Update: 25 Jul 2017

Price : $50

At a glance

  • Originator AB2 Bio
  • Class Anti-inflammatories
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 1 inhibitors; Interleukin 18 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Immunological disorders
  • Phase II Adult-onset Still's disease

Most Recent Events

  • 14 Jun 2017 Adverse events and efficacy data from a phase II trial in Adult-onset Still's disease presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 15 May 2017 Phase-III clinical trials in Immunological disorders (In adolescents, In children) in USA (SC) (NCT03113760)
  • 21 Apr 2017 AB2 Bio plans a phase III trial for Immunodeficiency disorders (In children, In adolescents) (NCT03113760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top